Verified Nov 2026
Batteries & E-Mobility
·

Bothell, Washington
·
Since 2014
SystImmune is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Bothell, Washington, with 100–200 employees and estimated revenue of $250–500M. The company develops cancer therapeutics using bispecific, multispecific, and tri-specific antibodies, plus antibody-drug conjugates, targeting solid tumors and hematologic indications. Iza-bren, its bispecific ADC, received FDA Breakthrough Therapy Designation for previously treated EGFR-mutated non-small cell lung cancer and has gained approvals in China for esophageal squamous cell carcinoma and nasopharyngeal carcinoma.
SystImmune at a glance
Revenue
$250-500M
Est. band
Employees
100-200
Founded
2014
Headquarters
Bothell, Washington
Certifications
ISO 13485
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
STABILITY SIGNALS
Established & active
12 years in operation (founded 2014).
Holds ISO 13485 certification(s) per public sources.
Overview
SystImmune is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Bothell, Washington, with 100–200 employees and estimated revenue of $250–500M. The company develops cancer therapeutics using bispecific, multispecific, and tri-specific antibodies, plus antibody-drug conjugates, targeting solid tumors and hematologic indications. Iza-bren, its bispecific ADC, received FDA Breakthrough Therapy Designation for previously treated EGFR-mutated non-small cell lung cancer and has gained approvals in China for esophageal squamous cell carcinoma and nasopharyngeal carcinoma.
At a glance
Attribute | Detail |
|---|---|
Founded | 2014 |
Headquarters | Bothell, Washington |
Employees | 100-200 |
Revenue | $250-500M (estimated) |
Primary capability | Batteries & E-Mobility |
Certifications | ISO 13485 |
What SystImmune makes
The company holds ISO 13485 certification and operates a facility in Chengdu, China, supporting development and commercialization of its oncology pipeline.
Certifications
SystImmune is associated with the following certifications in public sources. Confirm the certified scope for the specific plant producing your part:
ISO 13485 — simplify.jobs
Latest developments
2026-09-22 — SystImmune Receives FDA Clearance of IND Application for Bispecific Antibody SI-B037 (prnewswire.com)
2026-08-05 — SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer (prnewswire.com)
2026-07-17 — SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma PR Newswire (bluemountaineagle.com)
2026-06-22 — SystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in China PR Newswire (lagrandeobserver.com)
2026-05-21 — New Clinical Data for Izalontamab Brengitecan and Novel ADC Pipeline to be Presented at ASCO 2026 (prnewswire.com)
2026-05-20 — SystImmune expands its iza-bren programme again | ApexOnco - Clinical Trials news and analysis (apexonco.com)
Facilities
SystImmune is headquartered in Bothell, Washington. Public sources also reference these locations:
Chengdu, China — systimmune.com
Company details
SystImmune collaborates with Bristol Myers Squibb for markets outside China and maintains operations in Princeton, New Jersey, alongside its Washington headquarters. SystImmune was founded in 2014, has an estimated 100-200 employees, and is headquartered in Bothell, Washington. On the LightSource stability read it is rated "Established & active": 12 years in operation (founded 2014). Holds ISO 13485 certification(s) per public sources.
Frequently asked questions
What does SystImmune make?
SystImmune is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Bothell, Washington, with 100–200 employees and estimated revenue of $250–500M. The company develops cancer therapeutics using bispecific, multispecific, and tri-specific antibodies, plus antibody-drug conjugates, targeting solid tumors and hematologic indications. Iza-bren, its bispecific ADC, received FDA Breakthrough Therapy Designation for previously treated EGFR-mutated non-small cell lung cancer and has gained approvals in China for esophageal squamous cell carcinoma and nasopharyngeal carcinoma.
Where is SystImmune headquartered?
SystImmune is headquartered in Bothell, Washington (22213 30th Dr SE, Bothell, Washington, 98021-4901).
When was SystImmune founded?
SystImmune was founded in 2014.
How big is SystImmune?
SystImmune has an estimated 100-200 employees, with revenue in the $250-500M range (estimated).
What certifications does SystImmune hold?
SystImmune lists ISO 13485 on its website. Confirm the certified scope for the specific plant producing your part.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
